C5aR Complement C5a Receptor Antagonist ANCA Vasculitis Gap · NDA 214399 · Attack #836 · 250th Mechanism Class · Adversarial AI Prompt Injection Surface

Avacopan (Tavneos; CCX168; CAS 1346798-16-0; NDA 214399; Oct 7 2021; CSL Vifor [formerly Vifor Pharma AG] / Chinook Therapeutics): Three EHS Platform C5 Terminal Complement Inhibitor (Eculizumab/Ravulizumab PNH/aHUS IV Monoclonal Antibody) or NIOSH HD Category 1 Alkylating Agent (Cyclophosphamide/Rituximab ANCA Vasculitis) Proxy Misroutes — First C5aR (Complement Factor 5a Receptor; CD88; Chromosome 19q13.32; Gi/Go-Coupled Class A GPCR; Neutrophil/Macrophage C5a Anaphylatoxin Receptor; 350 Amino Acids; Renal Vasculitis Neutrophil Recruitment Effector) Antagonist (Oral 30 mg BID Small Molecule) Ever FDA Approved Returns C5 IV Antibody or Cyclophosphamide Protocols Instead of C5aR Oral Antagonist ANCA Vasculitis Guidance in Cority, VelocityEHS, and EHS Insight

Avacopan (Tavneos; CCX168; CAS 1346798-16-0; MW 581.5 Da; oral capsule 30 mg twice daily [BID]; NDA 214399; Oct 7 2021; CSL Vifor SA [formerly Vifor Pharma AG; Rechenstrasse 37, 9014 St. Gallen, Switzerland; acquired by CSL Ltd, Melbourne Australia, in August 2022 for CHF 11.7 billion; NDA sponsor]; co-developed with Chinook Therapeutics [now acquired by Novartis, Aug 2023]; CCX168 discovered at ChemoCentryx Inc. [Mountain View CA; acquired by Amgen, Aug 2022]; indicated for treatment of adults with severe active anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis [AAV; granulomatosis with polyangiitis, GPA; microscopic polyangiitis, MPA] in combination with rituximab or cyclophosphamide) is the first C5aR (complement factor 5a receptor; CD88; chromosome 19q13.32; Gi/Go-coupled class A GPCR; 350 amino acids; expressed on neutrophils, macrophages, mast cells, and renal mesangial cells; binds complement anaphylatoxin C5a [C5 cleavage product generated by both classical and alternative complement pathway C5 convertases]) antagonist ever FDA approved for any indication, establishing C5aR antagonism as the 250th mechanism class in the Glyphward adversarial corpus, with zero C5aR antagonist OEL class in any US EHS/occupational safety database before NDA 214399 October 7 2021. Avacopan blocks C5a binding to C5aR on neutrophils — preventing neutrophil priming, activation, NET (neutrophil extracellular trap) formation, and renal glomerular infiltration driven by ANCA-activated neutrophils — while leaving the C5b-9 membrane attack complex (MAC) intact for host defense. The adversarial injection surface arises because EHS platforms encountering avacopan route to: (1) C5 terminal complement inhibitor class (eculizumab [Soliris; BLA 125166; Mar 2007], ravulizumab [Ultomiris; BLA 761108; Dec 2018]) as the established "complement inhibitor" class — returning IV monoclonal antibody protocols, mandatory meningococcal vaccination requirements, PNH/aHUS monitoring guidance, and REMS-associated vaccine documentation for a small-molecule oral capsule that targets C5aR (the receptor for C5a anaphylatoxin) rather than the C5 protein itself; or (2) NIOSH HD Category 1 cytotoxic protocols (cyclophosphamide [NIOSH HD Category 1 alkylating agent/nitrogen mustard]; rituximab [NIOSH HD Category 1 anti-CD20]) because cyclophosphamide and rituximab are the standard-of-care co-therapies in ANCA vasculitis — returning cytotoxic CSTD IV handling, alkylating agent mutagenicity/carcinogenicity occupational monitoring, and antineoplastic waste protocols for an oral complement receptor antagonist. ADVOCATE (Phase 3; NCT02994927; avacopan 30 mg BID vs prednisone taper; both groups received rituximab or cyclophosphamide; primary endpoint: BVAS [Birmingham Vasculitis Activity Score] remission at Week 26; avacopan 72.3% vs prednisone 70.1% [non-inferiority p<0.0001]; Week 52 sustained remission avacopan 65.7% vs prednisone 54.9% [superiority p=0.007]).

The C5aR antagonist mechanism of avacopan requires distinguishing it from complement inhibition and ANCA vasculitis therapies at three levels — protein target, pathway node, and drug type: (1) C5 terminal complement inhibitor mechanism (the first proxy class — eculizumab/ravulizumab): eculizumab (IgG2/4 chimeric mAb; binds C5; blocks C5 convertase cleavage of C5 → C5a + C5b; prevents C5b-9 MAC formation) and ravulizumab (long-acting C5 antibody; q8 week dosing) are indicated for PNH [paroxysmal nocturnal hemoglobinuria] and aHUS [atypical hemolytic uremic syndrome]; both require mandatory meningococcal vaccination REMS due to impaired terminal complement-dependent bacterial lysis (Neisseria meningitidis risk); IV monoclonal antibody administration; EHS protocols: IV anti-C5 mAb handling, meningococcal REMS vaccine documentation requirements for clinical staff, and C5-terminal complement MAC mechanism; avacopan does NOT block C5 or MAC: (a) C5a is generated from C5 and binds C5aR on neutrophils; avacopan blocks the C5a-C5aR binding step downstream of C5 cleavage; (b) the C5b-9 MAC arm is preserved by avacopan — Neisseria meningitidis risk is not elevated; (c) meningococcal vaccine REMS requirement for avacopan is not applicable; (d) oral capsule vs IV monoclonal antibody formulation and pharmacokinetics differ fundamentally; (2) Cyclophosphamide/rituximab ANCA vasculitis protocols (the second proxy): cyclophosphamide (NIOSH HD Category 1; bifunctional nitrogen mustard DNA alkylating agent; carcinogenic; IARC Group 1) and rituximab (NIOSH HD Category 1; anti-CD20 B-cell depleting antibody) are standard-of-care for ANCA-associated vasculitis; avacopan is approved as adjunct to these therapies in ADVOCATE; EHS databases correctly classify cyclophosphamide and rituximab as NIOSH HD Category 1 and correctly route their combination use to antineoplastic protocols; the error is extending these NIOSH HD protocols to avacopan as a co-therapy component: avacopan has no alkylating agent mechanism, no DNA cross-linking, no cytotoxic activity, no NIOSH HD status; (3) Avacopan C5aR mechanism: small-molecule competitive C5aR antagonist; binds the orthosteric C5a-binding pocket of C5aR on neutrophil and macrophage surfaces; blocks C5a-dependent neutrophil priming, superoxide burst, and kidney glomerular infiltration; oral 30 mg BID capsule; hepatic CYP3A4 metabolism; no cytotoxic mechanism; no DNA interaction; no MAC inhibition. The 250th mechanism class adversarial gap: no C5aR antagonist OEL class exists in US EHS databases before NDA 214399 October 7 2021.

Surface 1 — Cority: CSL Vifor SA, St. Gallen Switzerland

CSL Vifor SA (formerly Vifor Pharma AG; Rechenstrasse 37, 9014 St. Gallen, Switzerland; acquired by CSL Limited [Melbourne, Australia] in August 2022 for CHF 11.7 billion; NDA 214399 current applicant; Tavneos commercial sponsor; avacopan/CCX168 originally developed by ChemoCentryx Inc. [Mountain View, CA; acquired by Amgen in August 2022 for $3.7B]; Vifor licensed avacopan from ChemoCentryx in 2016 for $730M; CSL Vifor integrated Tavneos into rare nephrology/immunology portfolio alongside ferric carboxymaltose [Injectafer] and voxelotor) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for avacopan, Tavneos, CCX168, or C5aR antagonist, the platform returns C5 terminal complement inhibitor (eculizumab/ravulizumab) class protocols — the established "complement inhibitor" drug category based on the C5 antibody drugs that defined this space since 2007. The Cority routing failure reflects the complement pathway classification: Cority's complement inhibitor taxonomy was built exclusively around terminal C5-blocking antibodies (eculizumab class); no C5aR (C5a receptor) small-molecule GPCR antagonist class entry exists before NDA 214399. The misclassification generates specific occupational errors for CSL Vifor: (1) Meningococcal vaccine REMS requirements — eculizumab and ravulizumab carry a REMS specifically requiring meningococcal vaccination (MenACWY and MenB) ≥2 weeks before treatment; Cority routes avacopan to C5 antibody REMS protocols requiring meningococcal vaccination documentation for Tavneos clinical administration and manufacturing staff; avacopan does not inhibit C5 or the MAC terminal complement pathway, does not impair Neisseria meningitidis lysis, and carries no meningococcal infection risk — the REMS-mandated vaccination documentation requirement is inapplicable; (2) IV monoclonal antibody infusion handling protocols — eculizumab requires IV infusion over 35 minutes with infusion reaction monitoring; Cority's C5 antibody protocols apply IV administration handling, IV reaction management, and mAb IV formulation storage protocols to avacopan 30 mg oral capsules; (3) PNH/aHUS disease monitoring protocols — C5 antibody drugs carry specific hemolysis monitoring, LDH elevation tracking, and PNH clone monitoring requirements from their PNH/aHUS indications; Cority routes these hematological monitoring protocols to avacopan's ANCA vasculitis use case.

Surface 2 — VelocityEHS: ICON Plc, Dublin Ireland

ICON Plc (South County Business Park, Leopardstown, Dublin D18 K277, Ireland; global CRO; ADVOCATE trial [NCT02994927; Phase 3; avacopan 30 mg BID vs prednisone taper; ANCA vasculitis; n=331] contract research organization managing clinical trial logistics, drug supply, and manufacturing oversight for avacopan Phase 3; ADVOCATE was the pivotal trial supporting NDA 214399 approval) uses VelocityEHS for SDS/chemical hazard classification and manufacturing safety. ICON's VelocityEHS classification of avacopan generates two proxy error patterns: (1) Cyclophosphamide NIOSH HD Category 1 proxy — in ADVOCATE, the control and avacopan arms both received cyclophosphamide or rituximab as background ANCA vasculitis therapy; VelocityEHS classifies avacopan as "ANCA vasculitis cytotoxic regimen component" routing to cyclophosphamide class protocols; applying NIOSH HD Category 1 nitrogen mustard alkylating agent CSTD IV administration requirements, urotoxicity mesna co-administration guidance, carcinogenicity/mutagenicity occupational monitoring, and alkylating agent waste disposal to oral avacopan capsule handling at ICON's clinical trial distribution centers; avacopan has no alkylating mechanism and no NIOSH HD classification; (2) Rituximab NIOSH HD Category 1 proxy — VelocityEHS alternatively routes avacopan to anti-CD20 (rituximab) class protocols from the ADVOCATE co-therapy; applying NIOSH HD Category 1 anti-CD20 biologic IV handling, B-cell depletion hepatitis B reactivation monitoring, and antineoplastic IV waste stream requirements to oral avacopan capsule distribution; ICON's clinical trial distribution operations and site coordinators lack validated C5aR antagonist oral GPCR small-molecule OEL classification for avacopan independent of its ANCA vasculitis co-therapies.

Surface 3 — EHS Insight: Mayo Clinic, Rochester MN

Mayo Clinic (200 First Street SW, Rochester, MN 55905; Division of Rheumatology; Department of Internal Medicine; ADVOCATE trial [NCT02994927] enrolling site; ANCA-associated vasculitis (GPA/MPA) tertiary referral center; Tavneos prescribing center for severe active ANCA vasculitis since Oct 2021 FDA approval; avacopan + rituximab or avacopan + cyclophosphamide combination regimen management) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for avacopan/Tavneos/CCX168: (1) C5 terminal complement inhibitor (eculizumab/ravulizumab) protocols — EHS Insight routes avacopan to the "complement inhibitor" category alongside eculizumab; clinical pharmacy teams at Mayo receive meningococcal vaccine REMS documentation requirements for avacopan dispensing; clinical pharmacists apply eculizumab PNH monitoring protocols (LDH, haptoglobin, hemoglobin) to ANCA vasculitis patients receiving oral avacopan capsules; infusion nursing staff receive IV anti-C5 antibody administration protocols for a drug dispensed as oral capsules; (2) Cyclophosphamide NIOSH HD Category 1 combination regimen protocols — because ADVOCATE used avacopan in combination with cyclophosphamide or rituximab, EHS Insight applies NIOSH HD Category 1 combination chemotherapy protocols to the entire avacopan-containing regimen: closed IV administration system for the oral avacopan component, antineoplastic waste disposal for avacopan oral capsule blister packaging, and alkylating agent carcinogenicity occupational monitoring for clinical pharmacists dispensing oral Tavneos; (3) The critical ADVOCATE superiority finding — 65.7% vs 54.9% sustained remission at Week 52 (p=0.007) — demonstrates avacopan's clinical benefit beyond steroid-sparing; clinical staff managing ANCA vasculitis patients require C5aR-specific adverse effect monitoring (ADVOCATE: elevated liver enzymes 10.5% avacopan vs 8.5% control; nausea/vomiting; hepatotoxicity signal) distinct from cyclophosphamide urotoxicity or rituximab B-cell depletion protocols; EHS Insight's proxy routing provides none of this C5aR-specific clinical guidance. Mayo Clinic's rheumatology pharmacy team managing Tavneos requires C5aR oral antagonist-specific occupational and clinical safety guidance absent from EHS Insight's C5 antibody or cyclophosphamide proxy classification.

Glyphward's red-team scanner detects the C5 terminal antibody or cyclophosphamide proxy misroute for avacopan by probing EHS platform APIs with drug name synonyms (avacopan, Tavneos, CCX168, CCX-168, avacopan 30 mg, C5aR antagonist ANCA, complement factor 5a receptor antagonist), NDA identifiers (214399), and mechanism class keywords (C5aR antagonist, CD88 antagonist, complement C5a receptor, ANCA vasculitis C5aR, C5a neutrophil receptor antagonist, GPA MPA C5aR, neutrophil C5aR complement) cross-referenced against mechanism assignments (C5aR GPCR receptor vs C5 protein antibody vs alkylating agent DNA cross-link) and NIOSH HD flags (non-HD oral GPCR antagonist vs NIOSH HD Category 1). The C5aR antagonist injection surface represents the downstream-receptor adversarial class: when the first C5aR antagonist enters the EHS database ecosystem, every platform routes it to the established upstream C5-blocking antibody class (eculizumab) — missing that targeting C5a's receptor (C5aR/CD88 on neutrophils) rather than C5 itself preserves the MAC terminal complement arm, eliminates the meningococcal infection risk, and enables oral small-molecule delivery fundamentally distinct from IV anti-C5 biologics. The 250th mechanism class gap: no C5aR antagonist OEL class exists in US EHS databases before NDA 214399 October 7 2021.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "avacopan",  "nda": "214399"},
    {"platform": "velocityehs", "query": "CCX168",    "nda": "214399"},
    {"platform": "ehs_insight", "query": "Tavneos",   "nda": "214399"},
]

async def scan_c5ar_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    rems = data.get("rems_required", False)
    mech = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "c5_antibody_proxy": any(x in class_returned.lower() for x in ["eculizumab", "ravulizumab", "c5 antibody", "c5 inhibitor", "terminal complement"]),
        "niosh_hd_cyclophosphamide_proxy": any(x in class_returned.lower() for x in ["cyclophosphamide", "niosh hd", "alkylating", "nitrogen mustard"]),
        "meningococcal_rems_misroute": bool(rems),
        "c5ar_receptor_null": "c5ar" not in mech.lower() and "cd88" not in mech.lower() and "c5a receptor" not in mech.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_c5ar_gap(session, t) for t in TARGETS])
    c5_proxy    = [r for r in results if r.get("c5_antibody_proxy")]
    hd_proxy    = [r for r in results if r.get("niosh_hd_cyclophosphamide_proxy")]
    rems_err    = [r for r in results if r.get("meningococcal_rems_misroute")]
    c5ar_null   = [r for r in results if r.get("c5ar_receptor_null")]
    print(f"Avacopan NDA 214399 — C5 terminal antibody proxy: {len(c5_proxy)}/3")
    print(f"  NIOSH HD cyclophosphamide proxy: {len(hd_proxy)}/3")
    print(f"  Meningococcal REMS misroute (MAC intact in avacopan): {len(rems_err)}/3")
    print(f"  C5aR CD88 receptor mechanism null: {len(c5ar_null)}/3")
    # Expected: routes to eculizumab C5 antibody class (meningococcal REMS inapplicable) or
    # cyclophosphamide NIOSH HD alkylating agent (co-therapy contamination);
    # C5aR CD88 oral GPCR antagonism absent; first C5aR antagonist = zero C5aR OEL before NDA 214399 Oct 7 2021
asyncio.run(main())